Yann-vai Le Bihan

London, ENG SM25NG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.

Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.

Journal: Journal of medicinal chemistry

Published: March 06, 2026

Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe.

Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe.

Journal: Journal of medicinal chemistry

Published: January 12, 2026

Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening.

Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening.

Journal: Scientific reports

Published: February 13, 2025

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma.

Journal: Blood

Published: July 02, 2024

Specific radiation damage to halogenated inhibitors and ligands in protein-ligand crystal structures.

Specific radiation damage to halogenated inhibitors and ligands in protein-ligand crystal structures.

Journal: Journal of applied crystallography

Published: May 09, 2024

A Degron Blocking Strategy Towards Improved CRL4CRBN Recruiting PROTAC Selectivity.

A Degron Blocking Strategy Towards Improved CRL4CRBN Recruiting PROTAC Selectivity.

Journal: Chembiochem : a European journal of chemical biology

Published: May 10, 2023

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells.

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells.

Journal: iScience

Published: April 12, 2023

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Journal: Journal of medicinal chemistry

Published: April 07, 2023

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.

Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.

Journal: Scientific reports

Published: July 04, 2022

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Journal: Journal of medicinal chemistry

Published: June 03, 2022

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Journal: Journal of medicinal chemistry

Published: June 02, 2022

Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70.

Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70.

Journal: Molecules (Basel, Switzerland)

Published: December 16, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026